mayo clinic glp-1 Obesity Week: study finds genetic biomarker may predict response after bariatric surgery A Mayo Clinic study found

The active ingredient in Wegovy can help people lose an average 21% of their initial body weight when taking the highest 7.2mg injection dose after 72 weeks

This was demonstrated by co-transfection and in vitro reciprocal pull-down assays (Fig

At the 2026 American Diabetes Association Scientific Sessions, AstraZeneca announced positive Phase 2b results for elecoglipron

Tirzepatide achieved superior glycemic control while simultaneously promoting weight loss, contrasting sharply with the weight gain typically associated with insulin therapy

Liraglutide causes large and rapid epicardial fat reduction

Patients should report new neck swelling, voice changes, or symptoms of thyroid dysfunction to their GP whilst taking GLP-1 medications